- Home
- ZIMV vs INZY Comparison
ZIMV vs INZY Comparison
Compare ZIMV & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- INZY
- Stock Information
- Founded
- ZIMV 2021
- INZY 2015
- Country
- ZIMV United States
- INZY United States
- Employees
- ZIMV N/A
- INZY N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- INZY Health Care
- Exchange
- ZIMV Nasdaq
- INZY Nasdaq
- Market Cap
- ZIMV 262.9M
- INZY 256.3M
- IPO Year
- ZIMV N/A
- INZY 2020
- Fundamental
- Price
- ZIMV $9.23
- INZY $4.00
- Analyst Decision
- ZIMV Hold
- INZY Buy
- Analyst Count
- ZIMV 2
- INZY 9
- Target Price
- ZIMV $10.00
- INZY $15.22
- AVG Volume (30 Days)
- ZIMV 129.0K
- INZY 1.0M
- Earning Date
- ZIMV 07-31-2025
- INZY 08-05-2025
- Dividend Yield
- ZIMV N/A
- INZY N/A
- EPS Growth
- ZIMV N/A
- INZY N/A
- EPS
- ZIMV N/A
- INZY N/A
- Revenue
- ZIMV $443,551,000.00
- INZY N/A
- Revenue This Year
- ZIMV $1.96
- INZY N/A
- Revenue Next Year
- ZIMV $1.95
- INZY N/A
- P/E Ratio
- ZIMV N/A
- INZY N/A
- Revenue Growth
- ZIMV N/A
- INZY N/A
- 52 Week Low
- ZIMV $8.15
- INZY $0.72
- 52 Week High
- ZIMV $22.40
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- ZIMV 49.25
- INZY 82.36
- Support Level
- ZIMV $8.39
- INZY $3.94
- Resistance Level
- ZIMV $9.08
- INZY $3.97
- Average True Range (ATR)
- ZIMV 0.26
- INZY 0.01
- MACD
- ZIMV -0.01
- INZY -0.09
- Stochastic Oscillator
- ZIMV 49.40
- INZY 66.67
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.